Stephan Harm

Dr. Stephan Harm

Stephan Harm is affiliated with the University for Continuing Education Krems as part of the Center for Biomedical Technology. His research focuses on biomedical engineering, hematology, and extracorporeal medicine, with a particular emphasis on blood purification technologies, anticoagulant mechanisms, and diagnostic assay optimization. Recent work includes studies on heparin effects, cytokine removal, and novel treatments for sepsis.

Research Interests

Harm’s investigations span antimicrobial peptide compatibility, endotoxin detection, and extracorporeal blood purification. His work often involves in vitro models to evaluate novel materials and techniques for clinical applications. Notable contributions include advancements in citrate anticoagulation methods and the optimization of lateral flow assays for SARS-CoV-2 detection.

Publications & Trends

Recent articles highlight advancements in blood compatibility testing for anticoagulants (2025), heparin’s role in endotoxin detection (2024), and cytokine removal via extracorporeal methods (2020). A consistent theme is the development of practical solutions for clinical challenges in nephrology and critical care.

Patents & Innovation

Harm co-invented "Dosing instructions for endotoxin-binding lipopeptides" (Patent WO2014001444A1), reflecting his focus on translational research. His work bridges material science and clinical practice, addressing gaps in antimicrobial and detoxification technologies.